Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 11:42 AM ET

Healthcare Equipment and Supplies

Company Overview of electroCore LLC

Company Overview

electroCore LLC operates as an electroceutical healthcare company that develops non-invasive vagus nerve stimulation (nVNS) therapies for the treatment of multiple conditions in neurology, psychiatry, and gastroenterology conditions. The company focuses on treatment of primary headache such as migraine and cluster headache conditions, along with trials in epilepsy, gastric motility disorders, depression, and anxiety conditions. It offers gammaCore, a vagus nerve stimulator. electroCore LLC was founded in 2005 and is headquartered in Basking Ridge, New Jersey with additional offices in Germany, Italy, Australia, Canada, New Zealand, and the United Kingdom.

150 Allen Road

Suite 201

Basking Ridge, NJ 07920

United States

Founded in 2005





Key Executives for electroCore LLC

Co-Founder, Chief Executive Officer and Director
Co-Founder and Chief Science Officer
Co-Founder, Principal Investor and Director
Chief Financial Officer
Chief Operating Officer
Compensation as of Fiscal Year 2015.

electroCore LLC Key Developments

electroCore Appoints Dr. Nader N Youssef as Chief Medical Officer

electroCore announced that Dr. Nader N Youssef has been appointed as Chief Medical Officer of the company. Nader brings more than 15 years of clinical, academic, and industry research experience to electroCore. He was previously Executive Director GI Global Clinical Development and Medical Affairs for NPS Pharmaceuticals including responsibility for overall regulatory and development strategy. Prior to NPS Nader was Director of Clinical Research at AstraZeneca USA where his assignments included developing agents with novel mechanisms of action focused on gastrointestinal pain and motility. He currently holds two appointments at the University of Medicine and Dentistry of New Jersey; one as Associate Professor of Pediatrics at the New Jersey Medical School and also, as Assistant Professor, at the School of Health Related Professions.

electroCore Appoints Patrick Fabbio as Chief Financial Officer

Patrick Fabbio has been appointed Chief Financial Officer of electroCore. Pat, who was previously VP Finance for NPS Pharmaceuticals, has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies. During his three years with NPS, he led the build-out of the global finance department and supported the $5.2 billion sale to Shire plc in February 2015. Prior to NPS, Pat served in senior financial positions including VP Finance, Catalent Pharma Solutions, CFO of Ikano Therapeutics, and senior corporate finance, commercial and transactional roles at Sanofi as well as Corporate Controller for Biomatrix Inc.

electroCore Llc Presents Latest Trail Advances on its gammaCore Therapy

electroCore LLC announced that it has presented at international Headache Meeting (EHMTICi) latest trail advances on its electroCore’s gammaCore therapy. Large scale randomized clinical trial of the gammaCore therapy in chronic cluster headache not only significantly reduced the number of cluster headache attacks beyond the best available standard of care, but also that patients experienced a greater reduction in number of attacks the longer they stayed on treatment. Treatment with gammaCore also resulted in meaningful improvements in quality of life and a reduction in the use of traditional rescue medications such as injectable sumatriptan and oxygen. Cluster headache is a condition that affects approximately the same number of people as multiple sclerosis, and is considered by experts to be one of the most painful medical conditions known to medicine. GammaCore’s demonstrated effects represent a significant breakthrough in the care of patients with this debilitating condition. More particularly, the Prevention and Acute Treatment of Chronic Cluster Headache (PREVA) randomized and open label trial data were presented in three poster presentations and at a breakout symposium on Saturday evening, highlighting the following key findings: Patients receiving gammaCore plus standard of care achieved a 43.4% reduction in the number of weekly cluster headache attacks compared with 12.5% (p=0.002) in patients treated with the best available standard of care. Treatment with gammaCore was more effective the longer patients remained on therapy. The quality of life measurements measured by EQ-5-3L VASiii and HIT-6iv were meaningful for those on gammaCore. Patients on gammaCore (in the randomized phase) reduced their use of sub cutaneous sumatriptan and oxygen by >60%. Nearly 64% indicated that they would recommend the use of gammaCore to a family member or friend. 56% of patients found treatment with gammaCore very easy to use. Treatment with gammaCore was safe and can be used in combination with drug treatments. Device related adverse events were primarily mild and transient. gammaCore is a revolutionary non-invasive vagus nerve stimulation (nVNS) therapy developed by electroCore. The patient delivers the therapy by holding the device on the neck over the vagus nerve for 90 seconds (link to picture) which painlessly delivers a proprietary electrical signal that activates specific fibers in the vagus nerve bundle. This stimulates the production of inhibitory transmitters in the central nervous system, and reduces the over expression of the excitatory neurotransmitter glutamate, which has been implicated in a number of headache disorders. The PREVA trial, which is part of the trial program ever carried out in cluster headache, was conducted at ten sites across Europe with 97 patients enrolled. Ninety-three were randomized to participate following the initial baseline data collection. Forty-five of the patients were randomly selected to use gammaCore plus their usual treatment and 48 to the best available standard of care. The baseline data collection period was two-weeks, followed by the four-week randomized phase. All the patients from both arms were asked to continue on active therapy for an additional four-week open label phase. The dosing of the therapy used in the PREVA trial was three, 120-second stimulations, delivered at two time points during each day.

Similar Private Companies By Industry

Company Name Region
Cardiox Corporation United States
ACP Medical Supply Corporation United States
Vertos Medical Inc. United States
minSURG International, Inc. United States
Ultimate Medical Services, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact electroCore LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at